Covid-19

Focus on potential best-in-class products
providing whole solution for coronavirus pandemic

Nasal Vaccine for Covid-19

Easy to Administer
Potential for Immunity in Elderly and Immunocompromised

Drawing on prior experience developing successful vaccine formulation candidates for a lethal  coronavirus (MERS), a team that has taken vaccines and therapeutics to market, Vaxcine has devised a novel nasal vaccine for Covid-19 that could generate greater immunity where it is needed than injectable approaches, be more convenient to use, be easier to distribute globally, and impose a lower burden on healthcare systems (self-administration potential).

Potential best-in-class through double-action using unique multi-array, antigen-presenting and Th2 cell mimetic, delivered via the nose.

Advantages

Easy to administer, nasal

Avoiding injections, more patient-friendly

Generating immunity where needed

Stopping virus at sites of entry eg lung, nose

Self-administration potential

Reducing health care administration costs

Rapid, world-wide roll-out potential

Simplified logistics/distribution and greater access for patients

No needles hazardous waste

No need for disposing needles

Potential for immunity in elderly and immunocompromised patients

Overcomes need for T-cell help

Rapid incorporation of new antigens

New antigens can be incorporated rapidly to keep up with viral mutations

Simplified clinical development

All formulation excipients are GRAS/Pharmacopoeia-listed

Oral Vaccine Against Covid-19

Easy to Administer and Distribute
Potential Strong IgA and IgG Immunity in Mucosal Surfaces

Vaxcine has devised an oral vaccine for the Covid-19 virus to generate greater immunity than injectable approaches for the important mucosal surfaces, be more convenient to take (oral, easy-to-swallow), easier to distribute globally and a lower burden to healthcare systems (with self-administration potential).  This development draws upon prior experience developing successful vaccine formulation candidates for a lethal coronavirus (MERS) in collaboration with the UK Defence Science and Technology Laboratory (DSTL) among other institutions and a team that has taken vaccines and therapeutics to market.

Advantages

Oral, Easy-to-swallow, administer

Avoiding injections, easier for elderly, children

Generating immunity where needed

Stopping virus in throat & lung

Self-administration potential

Reducing health care administration costs

Rapid, world-wide roll-out potential

Non-refrigeration, simplified logisitics/distribution and greater access for all

No hazardous waste

No need for disposing needles etc

Lower Toxicity Risk: Simplified clinical development

All formulation excipients are low risk GRAS/Pharmacopoeia listed

Rapid Ultrasensitive Point-of-Care Diagnostic for Covid-19

Detect Very Low Levels of Both Virus & Antibodies

Vaxcine, together with colleagues at Middlesex University and University College London, have devised a rapid, ultrasensitive, point-of-care biosensor for covid-19 (and potential new variants subsequently).  In contrast to other rapid diagnostic techniques the biosensor would detect very low levels of both virus and antibody in biological samples, a key requirement for determining infection and/or immunity. 

Advantages

Ultrasensitive biosensor

Detect very low titres of virus & antibodies
Detect molecules down to femtomolar range

Screening multiple viruses/antibodies

With one device

Rapid point-of-care diagnostic

<5 minute

Self-administered testing

Can be operated by patients themselves

Readily adaptable to new virus variants

As new mutations may develop

Mobile-enabled accessible surveillance

Over-the-counter & bluetooth connected

Rapid manufacturing

Synthesis of molecular probes and biosensor

Low cost of volume manufacturing

 And with multiple analytes, diagnostics

Stability reducing logistics costs

More stable than targeting with antibodies
Non-refrigeration, not sensitive to desiccation

Targeted Treatment for Covid-19

Virus-specific peptide aptamers stopping virus infecting human cells

Vaxcine has devised a unique, targeted peptide-based treatment for Covid-19.  This novel treatment candidate provides the opportunity of potential safety and efficacy advantages over other treatment approaches, and having broad application to both those with initial or well-established symptoms.

Advantages

Targeted treatment approach

Selectively blocking the virus in its tracks, safety and efficacy advantages potential

Lower cost than antibody approaches

Peptides less expensive than antibody-based approaches

Potential for inhaled and/or injected

Both inhaled and injected delivery approaches can be pursued

Rapid, world-wide roll-out potential

Peptides are low molecular weight, so less material required than for antibodies

Flexible, adaptable

Peptides can be modified in weeks to adapt to changes in virus/antigen profile

Avoids ADE risks

Avoids antibody-dependent enhancement (ADE) potential that antibody-based therapies face